Shanghai Shyndec Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Shanghai Shyndec Pharmaceutical has a total shareholder equity of CN¥15.1B and total debt of CN¥1.1B, which brings its debt-to-equity ratio to 7%. Its total assets and total liabilities are CN¥20.0B and CN¥4.9B respectively. Shanghai Shyndec Pharmaceutical's EBIT is CN¥1.4B making its interest coverage ratio -11.4. It has cash and short-term investments of CN¥7.0B.
Key information
7.0%
Debt to equity ratio
CN¥1.06b
Debt
Interest coverage ratio | -11.4x |
Cash | CN¥6.95b |
Equity | CN¥15.09b |
Total liabilities | CN¥4.88b |
Total assets | CN¥19.97b |
Recent financial health updates
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?
Aug 23Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?
Apr 30Recent updates
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?
Aug 23Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified
May 06Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?
Apr 30Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)
Apr 05Financial Position Analysis
Short Term Liabilities: 600420's short term assets (CN¥11.4B) exceed its short term liabilities (CN¥4.6B).
Long Term Liabilities: 600420's short term assets (CN¥11.4B) exceed its long term liabilities (CN¥245.5M).
Debt to Equity History and Analysis
Debt Level: 600420 has more cash than its total debt.
Reducing Debt: 600420's debt to equity ratio has reduced from 53.2% to 7% over the past 5 years.
Debt Coverage: 600420's debt is well covered by operating cash flow (248.8%).
Interest Coverage: 600420 earns more interest than it pays, so coverage of interest payments is not a concern.